Evolocumab reduces LDL cholesterol by approximately 60% consistently in patients with or without autoimmune/inflammatory diseases (AIID).
Patients with AIID exhibit higher baseline inflammation (hsCRP) but evolocumab does not significantly affect hsCRP levels.
Relative risk reduction of major cardiovascular events with evolocumab is greater in AIID patients (~42% reduction) compared to those without AIID (~14% reduction).
Key secondary outcomes including cardiovascular death, myocardial infarction, and stroke are significantly reduced more in the AIID subgroup using evolocumab.
